Navigation Links
Two-Year Results from the Medtronic ENDEAVOR III Trial Confirm,Stent's Positive Clinical Profile

MINNEAPOLIS--(BUSINESS WIRE)--Mar 26, 2007 - Two-year results from the Medtronic (MDT:NYSE) ENDEAVOR III trial confirm the positive clinical profile of the Endeavor(R) drug-eluting coronary stent and bring to nearly 1,300 the number of Endeavor patients who have at least two years of follow-up. Significantly, among those 1,300 Endeavor patients, there have been no reported cases of late stent thrombosis using the independent, pre-specified clinical trial protocol definitions for thrombosis. The results were presented today during the 56th Annual Scientific Session of the American College of Cardiology (ACC) conference in New Orleans.

Those in the 436-patient ENDEAVOR III trial are being followed out to five years. The clinical data reported at ACC as part of the study design indicate that the Endeavor stent continues to exhibit an excellent safety profile while delivering sustained efficacy and a low need for repeat procedures that is consistent with the overall Endeavor clinical program. At two years, the rate of Major Adverse Cardiac Events - a composite safety measure of death, repeat procedures and myocardial infarction (MI) - was reported to be 9.3% for Endeavor and 11.6% for the Cypher stent also studied in the ENDEAVOR III trial (p = 0.47). There was no statistically significant difference in the need for repeat procedures, or Target Lesion Revascularization (7.0% and 4.5% for Endeavor and Cypher, respectively, p = 0.50), or all-cause mortality (1.6% for Endeavor and 4.5% for Cypher, p = 0.14). However, fewer patients experienced heart attacks (MI) when treated with the Endeavor stent (0.6% vs. 3.6% for Cypher, p = 0.04) and the combined rate of heart attack and death also was statistically significantly lower among patients randomized to the Endeavor stent (2.2% vs. 7.1% for Cypher, p = 0.013).

Confidence in Endeavor safety

Worldwide, Medtronic has approximately 2,100 Endeavor patients enr olled in its multiple clinical trials, and the growing volume of positive data and number of patients with long-term follow-up continues to reinforce the stent's favorable safety and efficacy profile. The Endeavor stent is not yet approved for use in the United States.

"With two years of follow-up in nearly 1,300 patients and the volume of positive clinical data we've seen to date, we can continue to have confidence in Endeavor's clinical performance," said Martin Leon, M.D., principal investigator of the ENDEAVOR III clinical trial and Professor of Medicine at Columbia University School of Medicine. "As the Endeavor clinical program has matured, it has provided evidence that consistent and predictable patient outcomes are being sustained through time."

Scott Ward, senior vice president at Medtronic and president of the Vascular business, added: "The Endeavor clinical program continues to generate strong cumulative evidence regarding Endeavor's overall performance. Patients have been 99.7% free from overall stent thrombosis and we've seen no late stent thrombosis in our pooled clinical trials. In addition, Endeavor has demonstrated a sustained reduction in repeat procedures of 61% compared to the Medtronic Driver(R) bare metal stent and Endeavor's death/MI rates have been trending lower than bare metal stents."

Medtronic will present additional long-term data on Endeavor in the coming months. At the EuroPCR meeting in May, Medtronic will provide updated four-year and three-year results from the ENDEAVOR I and ENDEAVOR II trials respectively, as well as new data on the next-generation Endeavor Resolute drug-eluting stent. Results from the ongoing ENDEAVOR IV trial, another large randomized trial (1,548 patients) evaluating Endeavor against the Taxus stent made by Boston Scientific, are expected to be presented in the fall.

The Endeavor stent is made of a cobalt alloy and has a unique modular architecture designed to enhance deliverability over standard bare metal stents. In addition to the proprietary drug compound Zotarolimus, the Endeavor stent is coated with phosphorylcholine (PC), a polymer designed to simulate the outside surface of a red blood cell and mimic the structure of the natural cell membrane.

About Medtronic

Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology - alleviating pain, restoring health, and extending life for millions of people around the world.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's Annual Report on Form 10-K for the year ended April 28, 2006. Actual results may differ materially from anticipated results. -0-

       Caution: The Endeavor Drug Eluting Coronary Stent is an

 investigational device with an investigational drug (Zotarolimus) and

              is exclusively for clinical investigation.

Contact

Medtronic, Inc.
Public Relations:
Scott Papillon, 707-479-2418
or
Investor Relations:
Jeff Warren, 763-505-2696


'"/>




Related medicine technology :

1. Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN
2. Two-Year Patient Registry Results Support Safety and Efficacy of Cypher Sirolimus-Eluting Coronary Stent in Real World Uses
3. Point of Care Cardiac Analyzers Yield Rapid Cardiac Marker Results
4. Diagnosing Diabetes: Immediate HbA1c Results Improve Glycemic Control
5. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
6. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
7. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
8. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
9. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... -- Fotona, based in the U.S. and Europe ... Lightwalker dental laser at the upcoming 151 st Midwinter ... in booth #4815. The ST PRO is a full featured ... features of the award winning, industry leading Lightwalker ATS. At an ... be very attractive to many dentists hesitating to incorporate lasers ...
(Date:2/10/2016)... Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ), today ... and full year ended December 31, 2015. ... transformational year for Vanda with the continued growth of ... of HETLIOZ for Non-24," said Mihael H. Polymeropoulos, M.D., ... our U.S. product portfolio builds on this success and ...
(Date:2/10/2016)... 2016 A new report from business intelligence provider GBI ... the Alzheimer,s disease market will more than double from just under $5 billion ... Growth Rate (CAGR) of 11%. Canada , ... Spain , the UK, and Japan , ... --> Canada , France , ...
Breaking Medicine Technology:
(Date:2/10/2016)... NASHVILLE, Tenn. (PRWEB) , ... February 10, 2016 ... ... by the American Academy of Emergency Medicine , an emergency medicine ... of practice management services . , The American Academy of Emergency Medicine, ...
(Date:2/10/2016)... , ... February 10, 2016 , ... ... a master charity program created to assist the local community. Pledging to select ... leaders and nonprofit organizations in the area. Their goal is to bring community ...
(Date:2/10/2016)... FRANCISCO, Calif. (PRWEB) , ... February 10, 2016 , ... ... Best Water Brand. There were three leading bottled water brand owners that topped the ... services that enhance connectivity and optimize conversion. The premier brand was Tibet 5100, a ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... Dr. Jessica ... the practice is now accepting new dental patients and families in the North Metro ... dental care services from cleanings to cosmetic dentistry, and all in the most relaxing ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... bring together more than 200 of the country’s top healthcare executives to share ... “The true benefit of the Forum is the provider-centric perspective, experience, expertise and ...
Breaking Medicine News(10 mins):